

# Differences in white matter detected by *ex vivo* 9.4T MRI are associated with axonal changes in the R6/1 model of Huntington's Disease

Casella, C.<sup>1,2,§</sup>, Kelly, B.<sup>2</sup>, Murillo Bartolome, A.<sup>3</sup>, Mills-Smith, B.<sup>2</sup>, Parker, G.D.<sup>1,2</sup>, Von Ruhland, C.<sup>3</sup>, Syed, Y.A.<sup>2</sup>, Dion, V.<sup>3</sup>, Rosser, A.E.<sup>2,4</sup>, Metzler-Baddeley, C.<sup>1</sup>, Jones, D.K.<sup>1</sup>, Lelos, M.J.<sup>2</sup>

<sup>1</sup> Cardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology, Cardiff University, Cardiff, UK.

<sup>2</sup> School of Biosciences, Cardiff University, Cardiff CF10 3AX, U.K.

<sup>3</sup> UK Dementia Research Institute at Cardiff University, Cardiff CF24 4HQ, UK.

<sup>4</sup> B.R.A.I.N unit, Neurosciences and Mental Health Institute, School of Medicine, University Hospital of Wales, Heath Park, Cardiff, CF24 4HQ, U.K.

<sup>§</sup> Current address: Department of Perinatal Imaging and Health, School of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital, London, UK.

## Corresponding Author

Dr. Chiara Casella

Department of Perinatal Imaging and Health,  
School of Biomedical Engineering & Imaging Sciences,  
King's College London, St Thomas' Hospital, London, UK.

## Running Title

White matter microstructure alterations in the R6/1 model of Huntington's Disease

## Key words

Diffusion MRI; Quantitative magnetization transfer; Huntington's disease; White matter microstructure; R6/1 mice; Ultra-high field MRI.

## Abstract

White matter (WM) volume loss has been reported in people with Huntington's disease (HD), but the cellular basis of this deficit remains to be elucidated. To address this, we assessed ex vivo WM microstructure in the transgenic R6/1 mouse model of HD with magnetic resonance imaging (MRI) and studied the neurobiological basis of the MRI brain signals with histological and electron microscopy analyses in a separate cohort of age- and sex-matched mice. Differences in the macromolecular proton fraction (MPF) from quantitative magnetization transfer (qMT) as a proxy myelin measure, and the intra-axonal signal fraction (FR) from the composite hindered and restricted model of diffusion (CHARMED) as a proxy marker of axon density, were assessed alongside diffusion tensor imaging (DTI) parameters. A tractometry approach was employed to inspect region-specific differences across the corpus callosum (CC). Furthermore, voxel-based morphometry (VBM) and tract-based spatial statistics (TBSS) were used to explore brain-wise WM macro- and microstructure abnormalities. To gain insight into disease-associated impairments in attentional and visuospatial processing, a third cohort of age-matched mice was assessed with the 5-choice serial reaction time task (5-CSRTT). We report cognitive impairments in R6/1 mice and, by evaluating MRI and light and electron microscopy results, we show that this HD mouse model presents disruptions in axonal morphology (i.e. less complex, thinner axons) and organization (i.e. more densely packed axons). Furthermore, we show that, at least early in disease progression, R6/1 mice present a reduction in the expression or content of myelin-associated proteins without significant alterations in the structure of myelin sheaths. Finally, our findings indicate that neuroinflammation-driven glial and axonal swelling might also affect this mouse model early in disease progression. Crucially, we demonstrate the potential of FR, an in vivo estimate of axon density, as a novel MRI biomarker of HD-associated changes in WM microstructure.

## 1. Introduction

Huntington disease (HD), a neurodegenerative disorder leading to devastating cognitive, psychiatric and motor symptoms, cannot currently be cured. It is therefore a research priority to enhance understanding of how it develops and identify biomarkers to support therapy development. Recent investigations in HD have recognized alterations in the brain's white matter (WM) as relevant pathophysiological feature of HD<sup>1–12</sup>.

Specifically, WM atrophy has been shown both in animal models and in human HD carriers by histopathological post-mortem studies<sup>13–17</sup>, and MRI studies<sup>2,4,5,11,17–21</sup>. For example, structural neuroimaging studies of HD carriers have shown that WM atrophy can be found across several WM areas, including the corpus callosum (CC), the anterior commissure, internal and external capsules, and the cingulum. Furthermore, they suggest that WM changes happen very early in the disease course<sup>7,20,25–27</sup>. The severity of WM atrophy has been shown to correlate with predicted time to symptom onset in pre-manifest patients<sup>7,9,22</sup>, measures of motor dysfunction<sup>23</sup> and cognitive deficits<sup>19,24</sup>.

However, the cause of WM degeneration and its involvement in the development and advancement of HD are still not well understood. Notably, WM is composed of axons as well as myelin-producing oligodendrocytes, and it is unclear whether it is the loss of axons, myelin, or both, that drives the WM volumetric loss<sup>8</sup>. Accordingly, while most neuroimaging studies on WM alterations in HD have relied on measures of WM volume, WM volume loss as quantified using structural MRI is a rather unspecific marker of disease stage and progression as it is not sensitive to microstructure changes. As such, reductions in WM volume observed in structural neuroimaging studies can be the consequence of several factors, including a decrease in the number of axons because of Wallerian degeneration, a decrease in axon myelination, or a combination of both.

Although diffusion tensor MRI (DT-MRI)<sup>28</sup> has allowed a deeper understanding of WM organization at the microstructural level, DT-MRI metrics do not map specifically onto biological subcomponents of WM microstructure<sup>29</sup>. It is therefore very hard to interpret changes in DT-MRI metrics in terms of specific microstructural properties. Very different configurations of, for example, axonal packing, axonal size, and myelination may generate

very similar outcome measures (See Figure 2 in <sup>30</sup>). Accordingly, while some DT-MRI studies have suggested that WM changes in HD are a consequence of axonal injury rather than demyelinating mechanisms <sup>31</sup>, several others have indicated a role for myelin disturbance in HD pathology <sup>2,11,26,32–34</sup>.

In this work, we moved beyond volumetric and DT-MRI methods to obtain a greater insight into the neurobiological mechanisms underlying WM changes reported by MRI studies of HD carriers. For this purpose, we carried out a comprehensive WM microstructural assessment of the R6/1 mouse model of HD <sup>35,36</sup> using 9.4T MRI. We complemented gross measurements of WM atrophy performed with voxel-based morphometry (VBM) and fractional anisotropy (FA), axial diffusivity (AD) and radial diffusivity (RD) from DT-MRI <sup>37</sup>, with measures providing increased sensitivity to tissue microstructure and biochemical composition. Specifically, we measured the macromolecular proton fraction (MPF) from quantitative magnetization transfer (qMT) <sup>38</sup> as a proxy measure of myelin, and the restricted diffusion signal fraction (FR) from the composite hindered and restricted model of diffusion (CHARMED) <sup>39</sup> as a proxy measure of axon density <sup>29</sup>, in an attempt to disentangle the contribution of changes in axon microstructure versus myelin to HD pathology.

The R6/1 mouse model of HD expresses exon 1 of the human HD gene, with around 115 CAG repeats <sup>35</sup>. This line was amongst the first to be developed <sup>35</sup>, and presents a progressive phenotype and neuropathology, which occur early in life, with a reduced lifespan. Specifically, R6/1 mice exhibit age-related progressive changes in both motor and cognitive performance from as early as 2 months of age <sup>40</sup> and age-related neuronal loss, brain atrophy and mHTT accumulation <sup>41</sup>.

Despite evidence for grey matter (GM) pathology in R6/1 mice <sup>42,43</sup>, not many studies have performed an MRI characterization of WM alterations in this model. One previous study looking at gross volumetric changes in R6/1 mice, reported sparing of WM in this model, with no detectable differences in CC volume at either 9 or 17 weeks of age <sup>43</sup>. On the other hand, a recent *ex vivo* MRI study by Gatto and colleagues <sup>42</sup> reported alterations in WM microstructure metrics in the callosal genu of 11 weeks old R6/1 mice. These findings suggest that, although gross WM volumetric changes are not yet detectable in these mice early in HD progression, WM microstructure is impaired. However, their histological analysis

included markers of inflammation in GM, leaving cellular changes in WM alteration unexplored.

In the present study, the assessment of both macrostructural and microstructural changes in WM was performed with ex vivo MRI on the brains of 4 month old mice (N=7 WT and N=8 R6/1), with the aim of increasing understanding of the intricate cellular changes happening early in disease progression. Post-mortem imaging enabled longer scan times and limited the potential challenges commonly affecting live rodent scanning, such as movement artefacts. This in turn allowed data to be acquired with higher resolution, signal-to-noise and contrast-to-noise ratio <sup>44</sup>.

We used a separate cohort (N=13 WT and N=8 R6/1) to characterise disease-associated functional impairments in this model at 4 months of age. Specifically, we assessed attentional and visuospatial processing using the 5-choice serial reaction time task (5-CSRTT), as well as a range of simple motor tasks.

Finally, to gain insight into the neurobiological basis of imaging results, we used separate age- and sex-matched cohorts of mice to carry out light microscopy analysis of axons and myelin across all segments of the CC (N=9 WT and N=9 R6/1) and transmission electron microscopy (N=3 and N=3) analyses, to more precisely measure changes in axonal size, axonal density and myelin thickness. By leveraging the increased biological specificity obtained with this approach, we hoped to better inform previous knowledge and future research in the human condition.

## 2. Materials and Methods

### 2.1. Mice

All experimental procedures in this study (Table 1) followed protocols in accordance with the United Kingdom Animals (Scientific Procedures) Act of 1986. All experimental procedures performed on mice were approved by Cardiff University Ethical Review Process Committee and carried out under Home Office License P49E8C976.

Twelve (12 weeks old) female hemizygous R6/1 mice and wildtype littermates were purchased from Jackson Laboratories (Jax<sup>®</sup>, Bar Harbour, Maine, U.S.A.) to be scanned at 16 weeks of age. A final sample of 7 WT and 8 R6/1 mice was examined in this study, due to fixation artifacts present in the other samples, which made them inadequate for quantitative data analysis<sup>45</sup>.

An age- and sex-matched cohort of R6/1 and WT littermate mice was used for electron microscopy (N=3 WT and N=3 R6/1). For light microscopy, an age- and sex-matched cohort that consisted of N=9 WT and N=9 R6/1 were used, but sections from a 1:12 series were only included for analysis if they fell within the boundaries determined for the genu, body and splenium (see Section 2.5).

For motor and cognitive testing, an age- and mixed-sex cohort of mice consisting of WT (N=13) and R6/1 (N=8) was used. All these mice were injected with a control viral vector at P2, but subsequent to the behavioural testing, it was found that the vector lacked efficacy.

Prior to the experiment, all animals were housed in age- and sex-matched groups of between 1 and 5 mice, with mixed genotypes. Mice were subject to a 12-hour light:12-hour dark cycle with controlled room temperature ( $21 \pm 3$  °C) and relative humidity ( $60 \pm 3\%$ ). Each cage contained modest environmental enrichment including play tunnels and nesting material. All animals were weighed on a weekly basis to monitor general health.

**Table 1. Summary of assessments carried out in this study and sample description.**

Sample description	Assessment
7 WT and 8 R6/1 female mice tested at 4 months of age	<u>Ex vivo MRI:</u> <ul style="list-style-type: none"> <li>Tractometry of the CC (FA, AD, RD, FR and MPF)</li> <li>TBSS (FA, AD, RD, FR and MPF)</li> <li>VBM (anatomical data)</li> </ul>
13 WT and 8 R6/1 mixed-sex mice tested at 1-4 months of age	<u>Assessment of cognitive function:</u> <ul style="list-style-type: none"> <li>5-CSRTT</li> </ul> <u>Assessment of motor function:</u> <ul style="list-style-type: none"> <li>Balance beam</li> <li>Fixed rotarod</li> <li>Accelerated rotarod</li> <li>Vertical pole</li> <li>Locomotor activity</li> <li>Muscular strength</li> </ul>
9 WT and 9 R6/1 female mice tested at 4 months of age	<u>Light microscopy:</u> <ul style="list-style-type: none"> <li>NFL and MBP CC thickness and area fraction</li> </ul>
3 WT and 3 R6/1 female mice tested at 4 months of age	<u>Electron microscopy:</u> <ul style="list-style-type: none"> <li>Axon diameter of myelinated axons</li> <li>G-ratio of myelinated axons</li> </ul>

## **2.2 Assessment of visuospatial and attention function in the 5-CSRTT, and simple motor function**

Mice were trained on the 5-choice serial reaction times task (5-CSRTT), starting at 1 month of age. They were food restricted 5 days before training commenced and the 5-CSRTT testing concluded when mice were ~3 months old. The 5-CSRTT task requires the mouse to attend to the array until a stimulus light is briefly presented. Successful nose poke in the operandum where the stimulus flash occurred results in milkshake reward. Failure to poke in the correct hole results in a brief timeout, during which time the house light is presented briefly, before another trial commences. This task measures visuospatial attention during the interval prior to onset of the stimulus, when the mouse is required to attend to the 5-hole array to detect the flash of the stimulus light. During this same period, impulsive behaviours can be detected if mice respond inappropriately, rather than waiting for the stimulus presentation. Accuracy refers to the number of correct responses made out of the total number of trials that commenced. The reaction time is the duration of time between the stimulus onset and the mouse successfully responding in the nose poke operandum. Omissions refer to trials in which the stimulus light flashes, but no response is made during the 10 second limited hold period. Impulsivity refers to the number of nose pokes that occur during the interval prior to stimulus onset. Total trials refers to the total number of trials successfully completed during the test session.


Training was conducted as described in <sup>46</sup>. See Figure 1A. In brief, mice were initially trained to retrieve strawberry milkshake reward from the magazine, followed by training to respond in the central nosepoke of the array. During the initial training stages, the stimulus light was maintained for 10s to support learning, and this was gradually reduced to 2s, 1s, 0.5s and finally 0.25s stimulus duration.



From 3-4 months old, mice were maintained on an ad lib diet and tested on a range of simple motor tests, as described in <sup>40</sup>. Four trials of balance beam were conducted and data were averaged across the trials. Two trials of fixed rotarod (12 rotations per minute) were conducted and the data were analysed across these two trials. Data consisted of the mean latency to fall and the number of falls in a 60s period. Two trials of the accelerated rotarod were run and data were averaged across these two trials. Two trials of vertical pole were conducted and data were averaged across these two trials. Locomotor activity was also tracked in the open field using Ethovision over 5 minutes. Finally, muscular strength was assessed using the wire hang test for a maximum of 60s.

### **Statistical analysis:**

All data were analysed using GraphPad Prism 9. The accuracy data from 5-CSRTT data were analysed by AONVA with stimulus duration (10s-0.25s) as a within subjects factor and genotype as a between subjects factor. The remaining measures (reaction time, impulsivity, omissions and total trials) were analysed by independent subjects t-test. The vertical pole test data were analysed by independent subjects t-test. For the open field test the three measures (distance, velocity and duration) were analysed by independent subjects t-test. For the fixed rotarod, the two measures (Time (latency to fall) and number of falls in 60s) were analysed by independent subjects t-test. The accelerated data of time (latency to fall) was analysed by independent subjects t-test. For the grip test of muscle strength, the data were analysed by independent subjects t-test.



**Figure 1.** Analysis of cognitive and motor function in WT and R6/1 mice. (A) Schematic showing the 9-hole operant box apparatus with every other nosepoke hole available. (B) Impaired response accuracy in R6/1 mice is evident on the 5-CSRTT, even when the response stimulus duration was long during training (e.g., 10s). On the 5-CSRTT, R6/1 mice reacted to

*the stimulus more slowly (C) and omitted more responses (D). The R6/1 mice did not display impulsivity, as assessed by the number of hole pokes during the inter-trial interval (E), but they did complete fewer trials overall (F). R6/1 mice were slower on the vertical pole to reach the platform (G). In the open field, R6/1 mice travelled less far (H), were slower (I) and spent less time moving (J). On the fixed rotarod, R6/1 mice fell off more quickly (K) and fell more times across the 60s session (L). On the accelerod, R6/1 mice fell more quickly (N), but they did not show a difference in muscular strength on the hang wire test (N).*

### **2.3. Perfusion**

For imaging and light microscopy, mice were terminally anaesthetised *via* intraperitoneal injection of 0.3 ml Euthatal and then perfused through the left ventricle with approximately 60 ml of phosphate buffered saline (PBS). This was followed by infusion with about 150ml of 4% formaldehyde in PBS (pH 7.3) at a flow rate of 30ml/min. The temperature of the perfusates was maintained at room temperature and the pH of the formaldehyde was 7.2–7.4. After decapitation, the skulls were de-fleshed and post-fixed in 4% formaldehyde in PBS overnight. They were then transferred to a 25% sucrose solution and stored at 4°. For electron microscopy, a similar procedure was followed, except that the perfusate contained 2.5% Glutaraldehyde + 2.5% paraformaldehyde in PBS.

### **2.4. Ex vivo MRI Assessment of R6/1 brains**

#### **Tissue preparation:**

Brains were scanned in-skull, in order to preserve neural structures. The skulls were soaked in PBS and washed daily for three days, to regain some signal due to tissue rehydration<sup>47</sup>. The skulls were then carefully wiped with tissue paper, and immersed in Galden, a proton-free susceptibility-matching fluid in a 15ml syringe. The use of a syringe allowed any residual air bubbles to be pushed out, which might otherwise have affected MRI measurements. Immediately after scanning, skulls were returned to PBS and washed for three days, before being stored in a 25% sucrose - 0.1% sodium azide solution at 4°, to ensure tissue preservation.

## **Data acquisition:**

MRI acquisition was conducted *ex vivo* on a 9.4 Tesla (20 cm) horizontal-bore animal system (Bruker Biospin, Germany). This was equipped with BGA12-S (12cm inner bore size, integrated shims) gradients. A transmit 1H 500 Watt echo-planar imaging (EPI) volume coil was used with a phased array 4-channel surface coil and Paravision software (version 6.1, Bruker Biospin) were used for data acquisition.

The magnetic field homogeneity was optimized with a localized shimming procedure (Fastmap, Bruker Biospin) on a volume of interest placed in the centre of the brain. A PRESS-waterline sequence (Bruker BioSpin) was used with outer volume suppression without water suppression to evaluate water line width (TR/TE=2500/20ms respectively) to assess the shim performance and the peak line width of the water signal. Iterations were repeated until all line widths < 40 Hz.

The acquisition protocol consisted of a T<sub>1</sub>-weighted FLASH sequence, a multi-shell dMRI acquisition for DTI and CHARMED<sup>28,39</sup>, and an MT-weighted (MT-w) T<sub>1</sub> FLASH sequence. Additionally, the longitudinal relaxation rate of the system was estimated by acquiring T<sub>1</sub>-maps using T<sub>1</sub>-weighted FLASH images. A description of the acquisition parameters for each sequence is provided in Table 2.

**Table 2. Scan parameters.** All sequences were acquired at 9.4 Tesla. For each of the sequences, the main acquisition parameters are provided. MT: magnetization transfer; qMT: quantitative magnetization transfer. FoV: field of view; TE: echo time; TR: repetition time.

MRI acquisition parameters description	
<u>Anatomical scan</u>	
Pulse sequence	FLASH (3D)
Matrix size	192×192×72
FoV	19.2×19.2×18
TE, TR (ms)	4, 30
Flip angle (°)	36
Acquisition duration	20 min 44 s
<u>DTI/CHARMED</u>	

Pulse sequence	RARE
Matrix size	192×192
FoV	19.2×19.2
b-values (s/mm <sup>2</sup> ) – gradient directions	0, 1200 – 50, 2400 – 50, 4000 - 50
δ/Δ (ms)	6.8/16.3
Slice thickness (mm)	0.4
TE, TR (ms)	31, 3000
Flip angle (°)	90
Partial Fourier acceleration factor	1
Acquisition duration	12h 14 min
<u>T<sub>1</sub> map</u>	
Pulse sequence	FLASH (3D)
Matrix size	192×192×72
Fov	19.2×19.2×18
TE, TR (ms)	4, 30
Flip angles (°)	13, 17, 24, 36, 48
Acquisition duration	1 h 45 min
<u>MT/ qMT</u>	
Pulse sequence	FLASH 3D
Matrix size	192×192×72
FoV	19.2×19.2×18
TE, TR (ms)	5, 47
Off-resonance pulses (Hz/°)	0/350, 1000/350, 1500/350, 3000/350, 6000/350, 12000/350, 24000/350, 1000/950, 1500/950, 3000/950, 6000/950, 12000/950, 24000/950
Flip angles (°)	5
Acquisition duration	9h 50 min

### **Image processing:**

Skull-stripping was performed using the Rodent Bet Brain Extraction Tool, a modified version of the Brain Extraction Tool (BET; FSL v5.0) that can process rodent brains<sup>48</sup>.

**Anatomical data:** Processing of  $T_1$  anatomical images was performed using SPM8 (Wellcome Trust Institute of Neurology, University College London, UK, [www.fil.ion.ucl.ac.uk/spm](http://www.fil.ion.ucl.ac.uk/spm)) with the SPMouse toolbox (<http://spmhouse.org>) for animal brain morphometry<sup>49</sup>. This toolbox extends SPM's functionality with affine registration priors for mouse brains.

Specifically, a previously described mouse brain atlas<sup>50</sup> was used to register images from the brains of R6/1 mice with those of WT littermate controls. Following approximate manual registration using the SPM interface, images were bias-corrected and the affine priors supplied were used to register the images to the tissue probability maps. The registered images were then used to obtain GM, WM and CSF segmentations. The resulting WM segmentations were output in rigid template space and DARTEL<sup>51</sup> was used to create both non-linearly registered maps for each subject, and common templates for the cohort of animals. The warped WM portions for each mouse brain were modulated with the Jacobian determinant from the DARTEL registration fields to preserve tissue amounts, and smoothed with a Gaussian kernel of 400 $\mu$ m to produce maps for analysis<sup>52</sup>.

**Diffusion data:** Pre-processing of DWI data was performed with various tools including FSL<sup>53</sup>, MRtrix3<sup>54</sup>, ExploreDTI (v.4.8.3)<sup>55</sup>, and ANTS<sup>56</sup>. Each diffusion dataset was denoised<sup>57</sup> and corrected for field distortion<sup>58</sup> and Gibbs ringing artefacts<sup>59</sup>. Diffusion tensors were estimated using non-linearly weighted least squares (for  $b \leq 1500$  s/mm<sup>2</sup> data) providing the following quantitative scalar measures: FA, AD and RD. Motion and distortion artefacts in the CHARMED data were corrected according to the extrapolation method described in<sup>60</sup>. FR maps<sup>39</sup> were computed by fitting the CHARMED model to the DWI data, with an in-house software coded in MATLAB (The MathWorks, Natick, MA).

**qMT data:** MT-w images were corrected for Gibbs ringing artefacts<sup>59</sup> and co-registered to the MT-w volume with the most contrast using an affine registration (FLIRT, 12 degrees of freedom, mutual information). Subsequently, the MT-w images and  $T_1$ -maps were modelled by the two-pool Ramani's pulsed MT approximation<sup>61</sup>. This provided MPF maps, which were nonlinearly registered to the  $b=0$  s/mm<sup>2</sup> image using the MT-w volume with the most contrast as a reference, using FNIRT<sup>62</sup>. Accuracy of all registrations was confirmed by visual inspection.

### **Tractography of the CC:**


Multi-shell, multi-tissue, constrained spherical deconvolution (MSMT-CSD) <sup>63</sup> was applied to the pre-processed images to obtain voxel-wise estimates of the fiber orientation density functions (fODFs) <sup>64–66</sup> with maximal spherical harmonics order  $l_{max}=8$ . The fODFs were generated using a set of 3-tissue group-averaged response functions <sup>67</sup>. Seed points were positioned at the vertices of a 0.2x0.2x0.2mm grid superimposed over the image. The tracking algorithm interpolated local fODF estimates at each seed point and then propagated 0.05mm along orientations of each fODF lobe. This process was repeated until the minimally subtending peak magnitude fell below 0.05 or the change of direction between successive 0.05mm steps exceeded an angle of 40°. Tracking was then repeated in the opposite direction from the initial seed point. Streamlines whose lengths were outside a range of 2mm to 30mm were discarded.

To assess regionally specific effect of HD on the CC, tractography was performed in three different callosal segments (genu, body and splenium). 3D fibre reconstructions were performed interactively in the native space of each mouse in FiberNavigator <sup>68</sup> (Figure 2), using a combination of include and exclude regions of interest (ROIs), according to the following protocols:

**Genu:** Two ROIs were placed anterolateral to the most rostral portion of the corpus callosum in each hemisphere. This approach was used to capture the anteriorly arching fibres of the genu <sup>69</sup>. An exclusion ROI was used to exclude streamlines extending posteriorly to the genu on the sagittal plane, which make up the body of the CC.

**Body:** Two ROIs were placed ventral to the location of the cingulum and medial to the lateral ventricles (one in each hemisphere) <sup>69</sup>. Exclusion ROIs were used to exclude the genu and splenium (i.e., the anterior and posterior sections of the CC, respectively).

**Splenium:** Two ROIs were placed posterolateral to the most caudal section on the CC in the left and right hemisphere <sup>69</sup>. An exclusion ROI was used to remove streamlines extending anteriorly to the splenium.



**Figure 2. Tractography of the corpus callosum (CC).** Left: Representative figure of manually delineated segments of the CC (genu, body, and splenium). Right: Coronal view of whole-brain tractography (top) and fibers travelling through the manually delineated region of interests (ROIs), in rostral, sagittal and coronal views (bottom).

### **Statistical analysis:**

Statistical analyses were carried out using RStudio v1.1.456<sup>70</sup>, MATLAB (The MathWorks, Natick, MA), SPSS version 20119<sup>71</sup>, FSL<sup>53</sup> and the SPMouse toolbox (<http://spmmouse.org>) for animal brain morphometry<sup>49</sup>.

**Tractometry of the CC:** Microstructure differences were assessed in each of the three callosal segments. First, by taking each quantitative metric map (each registered to the  $b=0s/mm^2$  image during pre-processing), samples of each metric were obtained at each vertex of the reconstructed segments, and segment-specific medians were derived for FA, AD, RD, FR and MPF in MRtrix3<sup>54</sup>. Next, the overall mean was calculated, so that each dataset comprised 5 MRI-derived measures, mapped along 3 callosal segments.

**Investigation of group differences in callosal microstructure:** Two-way robust mixed ANOVAs were run for each metric (i.e., FA, RD, AD, FR, MPF), using the “bwtrim” R function from the WRS2 package<sup>72</sup>. This implements robust methods for statistical estimation and therefore provides a good option to deal with data presenting small sample sizes, skewed distributions and outliers<sup>73</sup>. Group was the between-subject factor and segment was the within-subject variable. Given that this robust method does not readily allow for post-hoc tests, we adopted a manual approach to further investigate significant effects. Trimmed



means for each segment were calculated using a trimming percentage consistent with the one used in the primary analysis (20%). After obtaining the trimmed means, pairwise comparisons were conducted with paired-samples t-tests, and p-values corrected for multiple comparisons using the false discovery rate (FDR). Across all analyses, outliers that were  $\pm 3$  standard deviations from the mean were removed.

***Automatic evaluation of WM atrophy using VBM:*** A general linear model to assess group differences in WM volume was evaluated using SPMMouse<sup>49</sup>. ICV was included as a covariate of no interest as this was shown to improve estimation of volume differences in previous literature<sup>49</sup>. ICV was calculated as the sum of voxels identified as GM, WM and CSF in native space for each animal, to model out the effect of different brain sizes. The sum of the WM tissue probability maps was used as explicit mask in the analysis. An adjusted p-value was calculated to control the voxel-wise FDR<sup>74</sup>.

***Assessment of brain-wise group differences in WM microstructure using TBSS:*** To perform a whole-brain analysis of WM microstructure changes associated with HD, the TBSS protocol<sup>75</sup>, modified for use in rodents<sup>76</sup> was used. All FA maps were submitted to a free-search for a best registration target in order to minimize the image warping required for each brain volume. Specifically, each volume was first registered to every other volume, and the one requiring minimum transformation to be registered to other volumes was selected as the best registration target. This target was used as a template into which the registration was performed. Following registration, a mean FA map was calculated, thinned to represent a mean FA skeleton, and an optimal threshold of 0.2 was applied to the mean FA skeleton to create a binary WM skeleton mask. The application of such threshold allowed to exclude from further analysis areas of the brain of low FA, including peripheral small tracts, where there may be high between-subject variability and GM, and it is therefore unsafe to assume good tract correspondence across subjects<sup>75</sup>.

The local FA-maximum was projected onto this WM skeleton. Subsequently, the voxel location of the local FA maximum was employed to project the respective AD, RD, FR and MPF values from that voxel onto the skeleton. Differences in microstructure measures between the two groups were assessed using voxel-wise independent t-tests (assessing areas where WT > R6/1 and R6/1 > WT). The randomize function (part of FSL) was used,

together with the TFCE algorithm<sup>77</sup>, generating cluster-size statistics based on 1000 random permutations. For multiple comparison correction, FDR correction was used with a threshold of  $p < 0.05$ .

## **2.5. Cytoarchitectural assessment of the CC using immunohistochemistry**

### **Tissue processing:**

WT and R6/1 brains were frozen on a sledge-microtome (Leitz, Wetzlar), cut into 40µm coronal sections, and collected in 12 parallel series. Sections were stored in ethylene glycol-based cryoprotectant at -20°C until processing. For immunostaining, 1:12 series of sections were quenched for 5 min using 10% H<sub>2</sub>O<sub>2</sub> (VWR, West Sussex, UK) and methanol (Sigma-Aldrich, Dorset, UK). Sections were blocked in 3% serum in Triton-X and Tris-buffered saline (TxTBS) for 1 h and incubated in a solution of TxTBS, 1% serum and primary antibodies raised against either myelin basic protein (MBP; 1:1000, Santa Cruz, cat. # SC1394R) or 68kDa Neurofilament (NFL; 1:500, Abcam, cat. # ab72997). Incubation in biotinylated-secondary antibody (1:200) was conducted for 2 h, then sections were incubated using an ABC kit (Vector Laboratories Ltd, Peterborough, Cambridgeshire) for 2 h. Proteins were visualised using 3,3'-diaminobenzidine (DAB), before mounting on to double-subbed 1% gelatinised slides (Thermo Scientific, Menzel Gläser). After dehydration and delipidisation in 100% xylene, slides were coverslipped using DPX mountant (Thermo Scientific, Raymond Lamb, Leicestershire, UK).

### **Determination of CC regions of interest (ROIs):**

To remain consistent with the DTI data, the CC was divided into three equal sections along its rostral-caudal axis to represent the genu, the body, and the splenium, mentioned rostral-caudal respectively. Bregma co-ordinates according to the Paxinos and Franklin Mouse Brain Atlas<sup>78</sup> were used: rostral genu 1.18mm to 0.86mm, caudal genu 0.14mm to 0.02mm, rostral body -0.1mm to -0.34mm, caudal body -0.94mm to 1.22mm and the splenium -1.3mm to -2.54mm. Three ROIs were taken from each brain hemisphere as well as 1 Medial

ROI (Figure 6A). For full brain slices, ROIs were placed in identical locations on each hemisphere where their quantifications were then averaged.

### **Data collection:**

Bright field LM was used under identical conditions to visualise NFL and MBP immunoreactivity using the Olympus BX50 light microscope. All images of the genu, body and splenium were captured at 100x magnification with MicrosoftVIS software. The viewing field, intensity and aperture measurements remained consistent throughout imaging to ensure the data processing was indistinguishable. For image quantification, using ImageJ software (NIH, v 1.53r), all images were quantified according to two different measurements, CC thickness ( $\mu\text{m}$ ) and area fraction (AF; i.e. the percentage of area with positive immunostaining). Images were converted to 8-bit greyscale prior to measurements being taken. For the analysis of the genu, body and splenium, all ROIs for each medial-lateral position were averaged together to determine a representative measurement (Figure 6A).

### **Statistical analysis:**

Statistical analysis was conducted using IBM SPSS Statistics 27. ANOVAs were conducted on data collected along the mediolateral axis, with the between-subjects factor of Genotype (WT vs R6/1) and the within-subjects factor of Region (Medial, Central-Medial, Central-Lateral and Lateral).

## **2.6. Ultra-structural analysis of axons in the CC using transmission electron microscopy**

### **Tissue processing:**

1mm thick slices in the central-medial region of the CC body segment were post-fixed for 2 hours in 2% (w/v) aqueous osmium tetroxide, block stained for 2 hours in 2% aqueous uranium acetate, dehydrated through graded isopropanol (50%, 70%, 90% and 2 x 100%) and 3 x propylene oxide for 15 minutes each and infiltrated with TAAB embedding resin

(50% in propylene oxide, 4 x neat resin for 1 hour each). Samples were placed into embedding moulds containing fresh resin and cured for 24 hours at 60°C.

For LM, semithin (0.5µm) sections were collected onto droplet of distilled water on glass slides, dried on a hot plate, stained with 0.5% aqueous toluidine blue, and mounted in Gurr's neutral mountant. Sections were examined with an Olympus BX51 research light microscope (Olympus Optical Co. (U.K.) Ltd, London, U.K) and images captured with a Zeiss AxioCam and Axiovision software (Carl Zeiss Vision GmbH, Hallbergmoos, Germany).

For electron microscopy, ultrathin (80-100nm) sections were collected onto 300 mesh copper grids, stained with Reynolds lead citrate (Reynolds, E. S. (1963)) and examined in a Hitachi HT7800 TEM (Hitachi High Tech Ltd., UK) at 100kV. Images captured with Radius software (EMSIS GmbH, Germany).

### **Image quantification:**

Five regions within the body of the CC were taken for quantification from randomly sampled 16.193µm<sup>2</sup> electron micrographs. The axon diameter of myelinated fibres and g-ratio of myelinated axons (calculated as 'inner diameter'/'outer diameter', where the inner diameter was that of the axon and the outer diameter include the myelin sheath) were manually quantified using ImageJ (<https://imagej.net>). Specifically, the inner and outer diameters were measured at the narrowest point of each axon, assuming them to be cylindrical.

### **Statistical analysis:**

Statistical analysis was conducted using IBM SPSS Statistics 27. For the axonal data, an ANOVA was conducted with Genotype and Axon (myelinated, non-myelinated) as factors. For the remaining data, independent-samples t-tests were conducted with WT and R6/1 data.

## Results

### 3.1. R6/1 mice present with early cognitive and motor impairments

On the 5-CSRTT, R6/1 mice showed impaired accuracy to respond in the correct nosepoke operandum across the training (e.g. 10s) and test sessions [Figure 1B;  $F(1,19)=8.833$ ,  $p<0.01$ ]. R6/1 mice were slower than WT mice [Figure 1C;  $t(19)=3.333$ ,  $p<0.01$ ], omitted more responses [Figure 1D;  $t(19)=2.531$ ,  $p<0.05$ ] and completed fewer trials [Figure 1F;  $t(19)=2.511$ ,  $p<0.05$ ], but they did not show impulsivity, as measured by the tendency to respond in the nosepoke operandum during the intertrial period [Figure 1E;  $t(19)=1.538$ ,  $p=n.s.$ ]. R6/1 mice showed less dexterity than WT mice on the vertical pole test [Figure 1G;  $t(19)=3.477$ ,  $p<0.01$ ]. On the open field test, R6/1 mice travelled less distance, were slower and spent less time moving than WT mice [Figure 1H-J, min  $t(19)=2.757$ ,  $p<0.05$ ]. On the fixed rotarod, R6/1 mice fell more quickly and fell more often in the 60s session [Figure 1K-L; min  $t(19)=3.865$ ,  $p=0.001$ ]. R6/1 mice also showed motor coordination deficits on the accelerod [Figure 1M;  $t(19)=2.809$ ,  $p<0.05$ ], but no differences in muscular strength were detected using the wire hang test [Figure 1N,  $t(19)=1.296$ ,  $p=n.s.$ ].

### 3.2. Tractometry analysis suggests that R6/1 mice present with alterations in apparent myelin, based on MBP, and axon density, based on FR, across the CC

Results for this analysis are plotted in Figure 3.

The mixed ANOVA for FA showed no significant effect of group [ $F(1, 7.4) = 0.31$ ,  $p = 0.592$ ]. On the other hand, a significant effect of segment [ $F(2, 6.05) = 7.51$ ,  $p = 0.02$ ] was detected, with the splenium showing significantly lower FA values compared to the body ( $p = 0.001$ ). No interaction effect between group and segment was present [ $F(2, 6.05) = 0.009$ ,  $p = 0.99$ ].


The mixed ANOVA for RD showed no significant effect of group [Figure 3;  $F(1, 7.2) = 0.16$ ,  $p = 0.69$ ], but a significant effect of segment [ $F(2, 6.4) = 15.15$ ,  $p = 0.003$ ], with the body showing significantly lower RD values compared to the splenium ( $p < 0.001$ ) and the genu

( $p=0.04$ ). No interaction effect between group and segment was detected [ $F(2, 6.4) = 0.29$ ,  $p = 0.75$ ].

The assessment of AD values showed no significant effect of group [Figure 3;  $F(1, 7.79) = 0.12$ ,  $p = 0.73$ ] but a significant effect of segment [ $F(2, 6.2) = 10.35$ ,  $p = 0.01$ ], with the body showing significantly lower AD compared to the genu ( $p=0.009$ ) and the splenium ( $p<0.001$ ). The group-by-segment interaction was not significant [ $F(2, 6.2) = 0.44$ ,  $p = 0.66$ ].

Significant main effects of group [ $F(1, 5.47) = 7.21$ ,  $p = 0.03$ ] and segment [ $F(2, 6.36) = 43.57$ ,  $p < 0.001$ ] on FR values were detected with the mixed ANOVA. Specifically, R6/1 mice presented overall higher FR values compared to WTs across all CC regions. The CC body presented higher FR values compared to the genu ( $p < 0.001$ ), the splenium presented lower FR values compared to body ( $p < 0.001$ ). No significant group-by-segment interaction was detected [ $F(2, 6.36) = 0.24$ ,  $p = 0.78$ ].


Finally, a significant effect of group [ $F(1, 6.59) = 4.77$ ,  $p = 0.05$ ] was detected on MPF, with R6/1 mice showing significantly lower values. No significant effect of segment [ $F(2, 6.15) = 2.34$ ,  $p = 0.17$ ], nor a significant group-by-segment interaction effect [ $F(2, 6.15) = 0.12$ ,  $p = 0.88$ ] were detected.



**Figure 3. Tractometry analysis of the corpus callosum (CC).** Quantification of FA, RD, AD, FR, and MPF in the genu, body and splenium of the CC. FR values were significantly higher and MPF values significantly lower in the brain of R6/1 mice across the whole CC. No significant group effects were detected for the other measures. Abbreviations: FA: fractional anisotropy; RD: radial diffusivity; AD: axial diffusivity; FR: restricted volume fraction; MPF: macromolecular proton fraction.

### 3.3. R6/1 mice present areas of increased WM volume

Figure 4 shows regions where WM volume was significantly higher in R6/1 brains than in WT controls ( $p < 0.05$ , FDR-corrected). Increased WM volume was detected in several areas such as the posterior callosum, external capsule and olfactory bulb.




**Figure 4. Group-differences in white matter volume.** Top: Maximum intensity projections (MIPs). Bottom: Maps of the  $t$ -value (whole brain voxel analysis at  $p < 0.05$  False discovery rate-corrected for multiple comparisons) overlaid on template white matter map, demonstrating increased volume in several areas across the brain of R6/1 mice.

### 3.4. TBSS reveals widespread increases in apparent axon density in R6/1 mice, based on FR, the restricted diffusion signal fraction

At first, a highly conservative FWE correction method was used for the TBSS analysis. This approach showed widespread increases in FR in the WM of R6/1 mice (Figure 5, top). When the voxel-wise analysis was repeated using a less conservative FDR correction of 5%




(Benjamin and Hochberg, 1995), additional WM changes were detected, including more extended increases in FR and some decreases in MPF in R6/1 brains (Figure 5, bottom).



**Figure 5. Tract-based spatial statistics (TBSS) analysis of white matter microstructure in R6/1 mice.** White matter microstructural alterations were detected across the brain of R6/1 mice, revealing widespread increases in FR and some areas of decreased MPF. Abbreviations: FR: intra-axonal signal fraction. MPF: macromolecular proton fraction.

### 3.5. Increased axonal staining and decreased myelin staining in R6/1 mice.

Representative images of MBP and NFL immunostaining in wildtype and R6/1 mice (Figure 6A-C). Across the medial-lateral axis, a higher percentage of CC area was immunostained for neurofilament light in R6/1 mice, as compared to wild-type mice, in the genu, body and splenium [Figure 6D-F; Splenium, min.  $F(1, 16)=5.00$ ,  $p<0.05$ ]. Conversely, a lower percentage area was stained for MBP in the R6/1 mice, as compared to wildtype mice, in the genu and body [Figure 6G-I; Genu, min.  $(F(1, 18)=6.03$ ,  $p<0.05)$ ].




**Figure 6: Immunohistochemical analysis of neurofilament light chain (NFL) and myelin basic protein (MBP) in WT and R6/1 mice.** (A) Low magnification (x12.5) MBP immunostaining showing ROIs for analysis along the medial-lateral axis, with one medial ROI and three lateralised ROIs (Central-Medial, Central-Lateral, Lateral). Scale bar = 500μm. (B) Representative MBP immunostaining at high magnification (x100) in central-lateral region of the CC body for WT and R6/1 mice. Staining encompasses whole image. Scale bar = 200μm. (C) Representative NFL immunostaining at high magnification in the central-medial region of

*the CC body. White arrows indicate staining in CC. Scale bar = 200µm. Analysis of the percentage area stained (area fraction) for the NFL stain within the genu (D), body (E) and splenium (F). Analysis of the percentage area stained (area fraction) for the MBP stain within the genu (G), body (H) and splenium (I). Analysis of the CC thickness for the NFL stain within the genu (J), body (K) and splenium (L). Analysis of the CC thickness for the MBP stain within the genu (M), body (N) and splenium (O). Data are presented as mean ± S.E.M.*

### **3.6. Thinner CC in R6/1 body based on NFL, but no difference in MBP**

For the NFL immunostain, no differences in CC thickness were observed in the genu [Figure 6J;  $F(1,17)=1.63$ , n.s.], but the R6/1 mice had thinner CC measurements in the body across the medial-lateral axis [Figure 6K;  $F(1, 13)=6.66$ ,  $p<0.05$ ] and in the central-medial region of the splenium [Figure 6L;  $F(3, 48)=3.47$ ,  $p<0.05$ ]. No differences in CC thickness were detected based on the MBP immunostain [Figure 6 M-O].



**Figure 7. Analysis of axons and myelin via electron microscopy.** (A) Representative TEM images from WT and R6/1 mice. White scale bars=1μm. (B) Total myelinated and non-myelinated axons in wildtype and R6/1 mice. (C) Mean g-ratio measurements for wildtype and R6/1 mice. (D) Mean axon diameter and (E) mean myelin thickness. (F) Percentage frequency of axons measuring 0.0- >1.4 μm in wildtype and R6/1 mice. N=3/group. Data are presented as mean ± S.E.M.

### 3.7. CC consists of thinner axons in R6/1 mice.

Representative electron microscopy images from wildtype and R6/1 mice are shown in Figure 7A. A reduced g-ratio was calculated for R6/1 mice compared to wildtype [Figure 7C;  $t(4)=2.74$ ,  $p=0.05$ ]. Analysis of the raw data revealed a thinner mean axonal diameter [Figure 7D;  $t(4)=3.31$ ,  $p<0.05$ ] and this is reflected in the greater frequency of thinner diameter

axons in R6/1 mice [Figure 7F]. No difference in myelin thickness was observed [Figure 7E;  $t(4) = -0.58$ , n.s.].

### 3 Discussion

We carried out a high-resolution *ex vivo* MRI assessment of WM alterations in the R6/1 mouse model of HD. We assessed 4 month-old mice to represent the early symptomatic stage of the disease<sup>40,42</sup>. In order to explore the cellular causes underlying the imaging phenotype, histological and electron microscopy analyses were performed in a separate cohort of age- and sex-matched mice. Additionally, we investigated the functional correlates of cellular changes by assessing cognitive and motor function in a third age-matched cohort. We report motor and cognitive impairments, as well as novel findings of WM changes in this model of HD, which may inform future research in the human condition.

The motor and cognitive impairments detected in 4-month old R6/1 mice in this study are consistent with previous evidence<sup>40,42</sup>. Interestingly, the cognitive deficits in response accuracy in the 5-CSRTT emerged early in training, even when the stimulus duration was long (10s) and the cognitive demands were low. This suggests that rather than an attentional deficit, R6/1 mice manifested a more global visuospatial impairment which disrupts their ability to code their responses in space. Although R6/1 mice were slower to respond, omitted more responses and completed fewer trials, they did not show any impulsivity. Additionally, they showed motor coordination, locomotor activity and dexterity impairments at 4 months old, but muscle strength was not affected. Given this disease-related functional impairment, we used high-resolution *ex vivo* imaging to explore the neurobiological differences between the genotypes.

MRI assessment of WM microstructural changes across the CC using a tractometry approach<sup>79,80</sup> revealed widespread increases in the intra-axonal signal fraction (FR) and decreased apparent myelin (MPF) in R6/1 mice. Interestingly, TBSS analysis uncovered widespread whole brain increases in FR, together with some regional decreases in MPF, suggesting that such alterations extend beyond the callosum. Importantly, the widespread FR increases detected in this study are consistent with findings from a recent MRI study on pre-symptomatic HD recently published by our group<sup>5</sup>, which demonstrated that FR is increased in the cortico-spinal tract of premanifest HD patients. This points to the potential of FR as a cross-species MRI marker of premanifest axonal changes in HD.

It has to be mentioned that the CHARMED model<sup>39</sup> utilised in this study to model the diffusion signal and obtain FR maps represents axons as parallel cylinders and thus cannot recover the effect of axonal orientation dispersion due to bending and fanning of axon bundles widespread throughout the brain<sup>81</sup>. More recent models such as the neurite orientation dispersion and density imaging (NODDI) model<sup>82</sup> support a description of WM beyond the most coherently-oriented structures and provide an estimate of the ‘spread’ of neurite orientations within a voxel with the orientation dispersion index (ODI).

Notably, a recent *ex vivo* MRI study by Gatto and colleagues<sup>42</sup> used NODDI to evaluate early microstructural changes in R6/1 mice, and reported increased ODI in the callosal genu at 11 weeks of age. The isotropic volume fraction (IsoVF), representing the signal coming from cerebrospinal fluid and other non-neurite tissue components, was also increased. On the other hand, the intracellular volume fraction (ICVF), representing the fraction of the MRI signal coming from the non-CSF compartment, was lower.

Based on the evidence provided by Gatto et al.<sup>42</sup> in combination with findings from the current study, we suggest that R6/1 mice present alterations in axonal morphology and structural organization, as reflected by more densely packed axons. Specifically, consistent with previous evidence from the R6/2 model<sup>83</sup>, R6/1 mice likely suffer from a reduction in the overall density of neurites, which include axons, dendrites and other neuronal processes, as indicated by lower IsoVF and ODI<sup>42</sup>. These neurites alterations in turn allow for a denser packing of the axons, leading to the higher FR detected in this study and in premanifest patients<sup>5</sup>, as well as to the increased axon immunostaining detected across the callosum in this study.

Notably, we also show that R6/1 mice present axons with disproportionately small diameters, as demonstrated by a thinner mean axonal diameter, and a greater frequency of thinner diameter axons detected with electron microscopy.

Previous evidence has shown an inverse relationship between axon diameter and axon density. Specifically, larger diameter axons take up more space, due not only to larger size, but also from the space demands of neighbouring glial cells<sup>84–86</sup>. Therefore, when there are fewer large diameter axons as shown here, or their morphology is less complex<sup>42,83</sup>, the space requirements go down. As a consequence, the *relative* proportion of smaller diameter

axons increases, leading to increases in the intra-axonal signal fraction and decreases in WM volume<sup>87</sup>. Overall, this is consistent with our findings of thinner callosal splenium as detected with axonal immunostaining, as well as the increases in FR detected in the MRI sample.

It is possible that axons in this model develop normally but then shrink because of the disease process. However, it might also be that R6/1 mice present abnormalities in the postnatal development of axons and studies evaluating axon microstructure in R6/1 mice earlier in development will be useful in assessing such possibility. Consistent with a developmental effect of the mutation, evidence shows that neurotypical development is associated with an increase in thick axons relative to thinner ones, which in turn tend to be present in a higher proportion early in life<sup>88</sup>.

In terms of myelin-related alterations in this model, histological analysis revealed that myelin staining was decreased in the genu and body, paralleling MPF decreases observed in the MRI sample. Interestingly, while MBP staining was decreased, electron microscopy did not detect significant alterations in the thickness of myelin sheaths in R6/1 mice.

Electron microscopy primarily focuses on the physical structure of myelin, such as the compactness of myelin layers, while MBP staining specifically targets the presence of MBP, which is a major component of myelin. This in turn suggests that, at least early in disease progression, R6/1 present a reduction in the expression or content of myelin-associated proteins, without significant alterations in the structure of myelin sheaths themselves. Such reductions might in turn be due to changes in gene expression, protein synthesis, or protein degradation.

Importantly, we detected increased WM volume in R6/1 mice with VBM. Interestingly, such an increase also concerned the splenium of the callosum, where NFL staining detected reduced thickness. Although these findings might seem counterintuitive, it is important to stress that VBM and NFL staining have different spatial resolutions and sensitivities. Specifically, while NFL staining provides fine-grained information about specific axonal changes, VBM captures broader structural changes that include factors other than axons. Therefore, an increase in volume as detected by VBM could be due to changes in the size or



quantity of brain tissue components other than axons, such as glial cells, blood vessels, or inflammation-related oedema and swelling.

Neuroinflammation is one of the central mechanisms involved in HD neuronal death, and reactive inflammatory processes are one of the most studied at the early stages of HD<sup>89</sup>. Accordingly, Gatto et al.<sup>42</sup> demonstrated the presence of neuroinflammatory processes from the early stage of the disease in R6/1 mice. Therefore, swelling of glial cells may have biased brain atrophy measurements<sup>90</sup> and may underlie the volume increases observed in this study. Inflammation-related swelling of glia may also explain the widespread increases FR observed in R6/1 mice, by reducing extracellular fluid and thus causing reduced diffusion in the extra-axonal space<sup>91,92</sup>.

To summarise, we report differences in WM microstructure in the R6/1 mouse model of HD. By combining insight from MRI, histology and electron microscopy, as well as evidence from previous studies, we suggest that such alterations are likely driven by axonal changes. Specifically, we show that R6/1 mice present disruptions in axonal morphology and organization. Furthermore, we show that, at least early in disease progression, R6/1 present a reduction in the expression or content of myelin-associated proteins, without significant alterations in the structure of myelin sheaths themselves. Finally, our findings indicate that neuroinflammation-driven glial and axonal swelling might also affect this mouse model early in disease progression.

These results extend previous findings on animal models and HD patients, all of which demonstrate alterations in WM microstructure as a significant feature of HD<sup>4,5,17,18,21,23,32,33,93–95</sup>. Crucially, we demonstrate cross-species convergence in FR increases, as we recently showed that alterations in this measure are also present in premanifest HD patients<sup>5</sup>. This points to the potential of FR as a novel MRI biomarker of HD-associated changes in WM microstructure.

Biomarkers constitute an important tool of translational science in medicine, thus the development of biomarkers that are useful and accessible in both animal models and humans affords improved translation of animal findings into humans and, likewise, the back-translation of imaging methods from humans to animal models<sup>96</sup>. Therefore, while inherent differences between species remain, the present findings may represent an important

preliminary step in the establishment of FR as a novel imaging biomarker of WM pathology in HD.

### **Methodological considerations**

The MRI data were obtained *ex vivo* from fixed tissue. As several factors, such as tissue fixation, sample temperature, and the acquisition scheme all have an effect on MRI measures, considerable care should be taken when extrapolating the present *ex vivo* findings to *in vivo* values<sup>97</sup>. However, the observed group differences should be valid, since any bias in terms of methodology should have the same effect of the two groups compared. Furthermore, in the present study, several steps were taken with regards to the perfusion and tissue preparation protocols to obtain optimal tissue quality. Such procedures were based on previous literature<sup>45</sup>, and consisted of the utilisation of liquid, rather than powder, perfusates, as well as delivery of perfusate at a low flow rate, in order to avoid blockage of the capillary beds and vessels' rupture. Additionally, the storage of tissue in a sodium azide solution enabled improved tissue conservation.

Another important thing to consider is that this study assessed three distinct cohorts of mice. Therefore, the nature of our study design limits our ability to establish causal relationships between variables. Nevertheless, our study provides an important stepping stone for future research assessing axonal alterations as a pathophysiological feature of HD.

## **Acknowledgements and funding source**

The present research was funded by a Wellcome Trust PhD studentship to CC (ref: 204005/Z/16/Z). MJL and AER were funded by an MRC Programme grant (MR/T033428/1). MJL was funded by an MRC-AMED grant (MR/V00560X/1) and an NC3Rs grant (NC/X001016/1), as well as a Parkinson's UK Fellowship (F-1502). DKJ was supported by a New Investigator Award (to DKJ) from the Wellcome Trust (ref: 096646/Z/11/Z) and a Strategic Award from the Wellcome Trust (ref: 104943/Z/14/Z). VD's laboratory is supported by the UK Dementia Research Institute (DRI- TAP2022FA2 and UK DRI-3006) which receives its funding from UK DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK. VD is further supported by a professorship from the Academy of Medical Sciences (AMSPR1\1014).

## **Conflicts of Interest**

The authors declare no conflicts of interest.

## **Data sharing and availability**

The data analysed during the current study and the respective analysis scripts are available from the corresponding author on reasonable request.

## References

1. Bardile CF, Garcia-Miralles M, Caron NS, et al. Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease. *Proceedings of the National Academy of Sciences*. 2019;116(19):9622-9627.
2. Bartzokis G, Lu PH, Tishler TA, et al. Myelin breakdown and iron changes in Huntington's disease: pathogenesis and treatment implications. *Neurochem Res*. 2007;32(10):1655-1664. doi:10.1007/s11064-007-9352-7
3. Casella C, Bourbon-Teles J, Bells S, et al. Drumming Motor Sequence Training Induces Apparent Myelin Remodelling in Huntington's Disease: A Longitudinal Diffusion MRI and Quantitative Magnetization Transfer Study. *Journal of Huntington's Disease*. 2020;9(3):303-320. doi:10.3233/JHD-200424
4. Casella C, Kleban E, Rosser AE, et al. Multi-compartment analysis of the complex gradient-echo signal quantifies myelin breakdown in premanifest Huntington's disease. *NeuroImage: Clinical*. 2021;30:102658.
5. Casella C, Chamberland M, Laguna PL, et al. Mutation-related magnetization-transfer, not axon density, drives white matter differences in premanifest Huntington disease: Evidence from in vivo ultra-strong gradient MRI. *Human Brain Mapping*. 2022;43(11):3439-3460. doi:10.1002/hbm.25859
6. Casella C, Lipp I, Rosser A, Jones DK, Metzler-Baddeley C. A Critical Review of White Matter Changes in Huntington's Disease. *Movement Disorders*. 2020;35(8):1302-1311. doi:10.1002/mds.28109
7. Ciarmiello A, Cannella M, Lastoria S, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. *J Nucl Med*. 2006;47(2):215-222.
8. Gregory S, Crawford H, Seunarine K, et al. Natural biological variation of white matter microstructure is accentuated in Huntington's disease. *Human Brain Mapping*. 2018;39(9):3516-3527. doi:10.1002/hbm.24191
9. Paulsen JS, Langbehn DR, Stout JC, et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. *J Neurol Neurosurg Psychiatry*. 2008;79(8):874-880. doi:10.1136/jnnp.2007.128728
10. Reading SAJ, Yassa MA, Bakker A, et al. Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. *Psychiatry Res*. 2005;140(1):55-62. doi:10.1016/j.psychres.2005.05.011
11. Rosas HD, Wilkens P, Salat DH, et al. Complex spatial and temporally defined myelin and axonal degeneration in Huntington disease. *NeuroImage: Clinical*. 2018;20:236-242. doi:10.1016/j.nicl.2018.01.029

12. Wang N, Yang XW. Huntington Disease's Glial Progenitor Cells Hit the Pause Button in the Mouse Brain. *Cell Stem Cell*. 2019;24(1):3-4. doi:10.1016/j.stem.2018.12.004
13. de la Monte SM, Vonsattel JP, Richardson EP. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. *J Neuropathol Exp Neurol*. 1988;47(5):516-525.
14. Gatto RG, Weissmann C. Diffusion tensor imaging in preclinical and human studies of huntington's disease: what have we learned so far? *Current Medical Imaging*. 2019;15(6):521-542.
15. Halliday GM, McRitchie DA, Macdonald V, Double KL, Trent RJ, McCusker E. Regional specificity of brain atrophy in Huntington's disease. *Exp Neurol*. 1998;154(2):663-672. doi:10.1006/exnr.1998.6919
16. Huang B, Wei W, Wang G, et al. Mutant huntingtin downregulates myelin regulatory factor-mediated myelin gene expression and affects mature oligodendrocytes. *Neuron*. 2015;85(6):1212-1226. doi:10.1016/j.neuron.2015.02.026
17. Jin J, Peng Q, Hou Z, et al. Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease. *Hum Mol Genet*. 2015;24(9):2508-2527. doi:10.1093/hmg/ddv016
18. Meng Y, Jiang J, Bachevalier J, Zhang X, Chan AWS. Developmental Whole Brain White Matter Alterations in Transgenic Huntington's Disease Monkey. *Sci Rep*. 2017;7. doi:10.1038/s41598-017-00381-8
19. Rosas HD, Tuch DS, Hevelone ND, et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. *Mov Disord*. 2006;21(9):1317-1325. doi:10.1002/mds.20979
20. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. *Lancet Neurol*. 2009;8(9):791-801. doi:10.1016/S1474-4422(09)70170-X
21. Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. *Lancet Neurol*. 2011;10(1):31-42. doi:10.1016/S1474-4422(10)70276-3
22. Stoffers D, Sheldon S, Kuperman JM, Goldstein J, Corey-Bloom J, Aron AR. Contrasting gray and white matter changes in preclinical Huntington disease. *Neurology*. 2010;74(15):1208-1216. doi:10.1212/WNL.0b013e3181d8c20a
23. Rosas HD, Lee SY, Bender AC, et al. Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection." *Neuroimage*. 2010;49(4):2995-3004.

24. Bohanna I, Georgiou-Karistianis N, Hannan AJ, Egan GF. Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease. *Brain Res Rev.* 2008;58(1):209-225. doi:10.1016/j.brainresrev.2008.04.001
25. Aylward EH, Nopoulos PC, Ross CA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. *J Neurol Neurosurg Psychiatry.* 2011;82(4):405-410. doi:10.1136/jnnp.2010.208264
26. Di Paola M, Phillips OR, Sanchez-Castaneda C, et al. MRI measures of corpus callosum iron and myelin in early Huntington's disease. *Hum Brain Mapp.* 2014;35(7):3143-3151. doi:10.1002/hbm.22391
27. Ruocco HH, Bonilha L, Li LM, Lopes-Cendes I, Cendes F. Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat. *J Neurol Neurosurg Psychiatry.* 2008;79(2):130-135. doi:10.1136/jnnp.2007.116244
28. Basser PJ, Mattiello J, LeBihan D. MR diffusion tensor spectroscopy and imaging. *Biophysical journal.* 1994;66(1):259-267.
29. De Santis S, Drakesmith M, Bells S, Assaf Y, Jones DK. Why diffusion tensor MRI does well only some of the time: Variance and covariance of white matter tissue microstructure attributes in the living human brain. *Neuroimage.* 2014;89(100):35-44. doi:10.1016/j.neuroimage.2013.12.003
30. Harrison JR, Bhatia S, Tan ZX, et al. Imaging Alzheimer's genetic risk using diffusion MRI: A systematic review. *NeuroImage: Clinical.* 2020;27:102359. doi:10.1016/j.nicl.2020.102359
31. Weaver KE, Richards TL, Liang O, Laurino MY, Samii A, Aylward EH. Longitudinal diffusion tensor imaging in Huntington's Disease. *Exp Neurol.* 2009;216(2):525-529. doi:10.1016/j.expneurol.2008.12.026
32. Bourbon-Teles J, Bells S, Jones DK, Coulthard E, Rosser A, Metzler-Baddeley C. Myelin Breakdown in Human Huntington's Disease: Multi-Modal Evidence from Diffusion MRI and Quantitative Magnetization Transfer. *Neuroscience.* 2019;403:79-92. doi:10.1016/j.neuroscience.2017.05.042
33. Di Paola M, Luders E, Cherubini A, et al. Multimodal MRI analysis of the corpus callosum reveals white matter differences in presymptomatic and early Huntington's disease. *Cereb Cortex.* 2012;22(12):2858-2866. doi:10.1093/cercor/bhr360
34. Mascalchi M, Lolli F, Della Nave R, et al. Huntington disease: volumetric, diffusion-weighted, and magnetization transfer MR imaging of brain. *Radiology.* 2004;232(3):867-873. doi:10.1148/radiol.2322030820
35. Mangiarini L, Sathasivam K, Seller M, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. *Cell.* 1996;87(3):493-506. doi:10.1016/s0092-8674(00)81369-0

36. Naver B, Stub C, Møller M, et al. Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. *Neuroscience*. 2003;122(4):1049-1057. doi:10.1016/j.neuroscience.2003.08.053
37. Pierpaoli C, Basser PJ. Toward a quantitative assessment of diffusion anisotropy. *Magn Reson Med*. 1996;36(6):893-906.
38. Henkelman RM, Huang X, Xiang QS, Stanisz GJ, Swanson SD, Bronskill MJ. Quantitative interpretation of magnetization transfer. *Magn Reson Med*. 1993;29(6):759-766.
39. Assaf Y, Basser PJ. Composite hindered and restricted model of diffusion (CHARMED) MR imaging of the human brain. *Neuroimage*. 2005;27(1):48-58. doi:10.1016/j.neuroimage.2005.03.042
40. Brooks SP, Janghra N, Workman VL, Bayram-Weston Z, Jones L, Dunnett SB. Longitudinal analysis of the behavioural phenotype in R6/1 (C57BL/6J) Huntington's disease transgenic mice. *Brain Res Bull*. 2012;88(2-3):94-103. doi:10.1016/j.brainresbull.2011.01.010
41. Bayram-Weston Z, Jones L, Dunnett SB, Brooks SP. Light and electron microscopic characterization of the evolution of cellular pathology in the R6/1 Huntington's disease transgenic mice. *Brain Res Bull*. 2012;88(2-3):104-112. doi:10.1016/j.brainresbull.2011.07.009
42. Gatto RG, Weissmann C, Amin M, et al. Evaluation of early microstructural changes in the R6/1 mouse model of Huntington's disease by ultra-high field diffusion MR imaging. *Neurobiology of Aging*. 2021;102:32-49. doi:10.1016/j.neurobiolaging.2021.02.006
43. Rattray I, Smith EJ, Crum WR, et al. Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the R6/1 Mouse Model of Huntington's Disease. *PLOS ONE*. 2013;8(12):e84726. doi:10.1371/journal.pone.0084726
44. Holmes HE, Powell NM, Ma D, et al. Comparison of In Vivo and Ex Vivo MRI for the Detection of Structural Abnormalities in a Mouse Model of Tauopathy. *Front Neuroinform*. 2017;11. doi:10.3389/fninf.2017.00020
45. Cahill LS, Laliberté CL, Ellegood J, et al. Preparation of fixed mouse brains for MRI. *Neuroimage*. 2012;60(2):933-939.
46. Yhnell E, Lelos MJ, Dunnett SB, Brooks SP. Cognitive training modifies disease symptoms in a mouse model of Huntington's disease. *Exp Neurol*. 2016;282:19-26. doi:10.1016/j.expneurol.2016.05.008
47. Petiet A, Delatour B, Dhenain M. Models of Neurodegenerative Disease – Alzheimer's Anatomical and Amyloid Plaque Imaging. In: Schröder L, Faber C, eds. *In Vivo NMR Imaging*. Vol 771. Humana Press; 2011:293-308. doi:10.1007/978-1-61779-219-9\_16

48. Wood TC, Lythgoe DJ, Williams SC. rBET: making BET work for rodent brains. In: Vol 21. ; 2013:2706.
49. Sawiak, Wood NI, Williams GB, Morton AJ, Carpenter TA. Voxel-based morphometry with templates and validation in a mouse model of Huntington's disease. *Magnetic resonance imaging*. 2013;31(9):1522-1531.
50. Sawiak S, Wood N, Williams G, Morton A, Carpenter T. SPMMouse: A new toolbox for SPM in the animal brain. In: ; 2009:18-24.
51. Ashburner J. A fast diffeomorphic image registration algorithm. *Neuroimage*. 2007;38(1):95-113. doi:10.1016/j.neuroimage.2007.07.007
52. Gary C, Lam S, Hérard AS, et al. Encephalopathy induced by Alzheimer brain inoculation in a non-human primate. *acta neuropathol commun*. 2019;7(1):126. doi:10.1186/s40478-019-0771-x
53. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. *Neuroimage*. 2004;23 Suppl 1:S208-219. doi:10.1016/j.neuroimage.2004.07.051
54. Tournier JD, Smith R, Raffelt D, et al. MRtrix3: A fast, flexible and open software framework for medical image processing and visualisation. *NeuroImage*. 2019;202:116137. doi:10.1016/j.neuroimage.2019.116137
55. Leemans A, Jeurissen B, Sijbers J, Jones D. ExploreDTI: a graphical toolbox for processing, analyzing, and visualizing diffusion MR data. In: *Proc Intl Soc Mag Reson Med*. Vol 17. ; 2009.
56. Avants BB, Tustison NJ, Song G, Cook PA, Klein A, Gee JC. A reproducible evaluation of ANTs similarity metric performance in brain image registration. *Neuroimage*. 2011;54(3):2033-2044. doi:10.1016/j.neuroimage.2010.09.025
57. Veraart J, Fieremans E, Novikov DS. Diffusion MRI noise mapping using random matrix theory. *Magn Reson Med*. 2016;76(5):1582-1593. doi:10.1002/mrm.26059
58. Andersson JLR, Skare S, Ashburner J. How to correct susceptibility distortions in spin-echo echo-planar images: application to diffusion tensor imaging. *Neuroimage*. 2003;20(2):870-888. doi:10.1016/S1053-8119(03)00336-7
59. Kellner E, Dhital B, Kiselev VG, Reiser M. Gibbs-ringing artifact removal based on local subvoxel-shifts. *Magn Reson Med*. 2016;76(5):1574-1581. doi:10.1002/mrm.26054
60. Ben-Amitay S, Jones DK, Assaf Y. Motion correction and registration of high b-value diffusion weighted images. *Magn Reson Med*. 2012;67(6):1694-1702. doi:10.1002/mrm.23186



61. Ramani A, Dalton C, Miller DH, Tofts PS, Barker GJ. Precise estimate of fundamental in-vivo MT parameters in human brain in clinically feasible times. *Magnetic Resonance Imaging*. 2002;20(10):721-731. doi:10.1016/S0730-725X(02)00598-2
62. Andersson JL, Jenkinson M, Smith S. Non-linear registration, aka spatial normalisation. *FMRIB technical report TR07JA2*. 2007;22.
63. Jeurissen B, Tournier JD, Dhollander T, Connelly A, Sijbers J. Multi-tissue constrained spherical deconvolution for improved analysis of multi-shell diffusion MRI data. *NeuroImage*. 2014;103:411-426.
64. Descoteaux M, Deriche R, Knosche TR, Anwander A. Deterministic and probabilistic tractography based on complex fibre orientation distributions. *IEEE transactions on medical imaging*. 2008;28(2):269-286.
65. Tournier JD, Calamante F, Gadian DG, Connelly A. Direct estimation of the fiber orientation density function from diffusion-weighted MRI data using spherical deconvolution. *Neuroimage*. 2004;23(3):1176-1185.
66. Tournier JD, Calamante F, Connelly A. Robust determination of the fibre orientation distribution in diffusion MRI: non-negativity constrained super-resolved spherical deconvolution. *Neuroimage*. 2007;35(4):1459-1472.
67. Dhollander T, Raffelt D, Connelly A. Unsupervised 3-tissue response function estimation from single-shell or multi-shell diffusion MR data without a co-registered T1 image. In: Vol 5. ; 2016:5.
68. Chamberland M, Whittingstall K, Fortin D, Mathieu D, Descoteaux M. Real-time multi-peak tractography for instantaneous connectivity display. *Front Neuroinform*. 2014;8. doi:10.3389/fninf.2014.00059
69. Catani M, Thiebaut de Schotten M. A diffusion tensor imaging tractography atlas for virtual in vivo dissections. *Cortex*. 2008;44(8):1105-1132. doi:10.1016/j.cortex.2008.05.004
70. Team Rs. RStudio: integrated development for R. *RStudio, Inc, Boston, MA URL* <http://www.rstudio.com>. 2015;42:14.
71. Armonk N. IBM Corp. SPSS Statistics for windows, Version 20.0. Published online 2011.
72. Mair P, Wilcox R. Robust statistical methods in R using the WRS2 package. *Behavior Research Methods*. 2020;52(2):464-488. doi:10.3758/s13428-019-01246-w
73. Wilcox RR. *Introduction to Robust Estimation and Hypothesis Testing*. Academic Press; 2011.
74. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B (Methodological)*. 1995;57(1):289-300.

75. Smith SM, Jenkinson M, Johansen-Berg H, et al. Tract-based spatial statistics: Voxelwise analysis of multi-subject diffusion data. *NeuroImage*. 2006;31(4):1487-1505. doi:10.1016/j.neuroimage.2006.02.024
76. Sierra A, Laitinen T, Lehtimäki K, Rieppo L, Pitkänen A, Gröhn O. Diffusion tensor MRI with tract-based spatial statistics and histology reveals undiscovered lesioned areas in kainate model of epilepsy in rat. *Brain Structure and Function*. 2011;216(2):123-135.
77. Smith SM, Nichols TE. Threshold-free cluster enhancement: addressing problems of smoothing, threshold dependence and localisation in cluster inference. *Neuroimage*. 2009;44(1):83-98. doi:10.1016/j.neuroimage.2008.03.061
78. Franklin KB, Paxinos G. *Paxinos and Franklin's the Mouse Brain in Stereotaxic Coordinates, Compact: The Coronal Plates and Diagrams*. Academic press; 2019.
79. Jones DK, Travis AR, Eden G, Pierpaoli C, Basser PJ. PASTA: pointwise assessment of streamline tractography attributes. *Magnetic Resonance in Medicine: An Official Journal of the International Society for Magnetic Resonance in Medicine*. 2005;53(6):1462-1467.
80. Bells S, Cercignani M, Deoni S, et al. Tractometry—comprehensive multi-modal quantitative assessment of white matter along specific tracts. In: Vol 678. ; 2011:1.
81. Bürgel U, Amunts K, Hoemke L, Mohlberg H, Gilsbach JM, Zilles K. White matter fiber tracts of the human brain: three-dimensional mapping at microscopic resolution, topography and intersubject variability. *Neuroimage*. 2006;29(4):1092-1105.
82. Zhang H, Schneider T, Wheeler-Kingshott CA, Alexander DC. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. *Neuroimage*. 2012;61(4):1000-1016. doi:10.1016/j.neuroimage.2012.03.072
83. Klapstein GJ, Fisher RS, Zanjani H, et al. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. *Journal of neurophysiology*. 2001;86(6):2667-2677.
84. Barres BA. The mystery and magic of glia: a perspective on their roles in health and disease. *Neuron*. 2008;60(3):430-440.
85. Lamantia A, Rakic P. Cytological and quantitative characteristics of four cerebral commissures in the rhesus monkey. *Journal of Comparative Neurology*. 1990;291(4):520-537.
86. Oberheim NA, Takano T, Han X, et al. Uniquely hominid features of adult human astrocytes. *Journal of Neuroscience*. 2009;29(10):3276-3287.
87. Raven EP, Veraart J, Kievit RA, et al. In vivo evidence of microstructural hypo-connectivity of brain white matter in 22q11.2 deletion syndrome. *Mol Psychiatry*. Published online July 26, 2023:1-11. doi:10.1038/s41380-023-02178-w

88. Zikopoulos B, Liu X, Tepe J, Trutzel I, John YJ, Barbas H. Opposite development of short- and long-range anterior cingulate pathways in autism. *Acta Neuropathol.* 2018;136(5):759-778. doi:10.1007/s00401-018-1904-1
89. Politis M, Lahiri N, Niccolini F, et al. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers. *Neurobiology of Disease.* 2015;83:115-121. doi:10.1016/j.nbd.2015.08.011
90. Andravizou A, Dardiotis E, Artemiadis A, et al. Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options. *Autoimmunity Highlights.* 2019;10(1):7. doi:10.1186/s13317-019-0117-5
91. Arfanakis K, Houghton VM, Carew JD, Rogers BP, Dempsey RJ, Meyerand ME. Diffusion tensor MR imaging in diffuse axonal injury. *AJNR Am J Neuroradiol.* 2002;23(5):794-802.
92. Stidworthy MF, Genoud S, Suter U, Mantei N, Franklin RJM. Quantifying the early stages of remyelination following cuprizone-induced demyelination. *Brain Pathol.* 2003;13(3):329-339. doi:10.1111/j.1750-3639.2003.tb00032.x
93. Crawford HE, Hobbs NZ, Keogh R, et al. Corpus callosal atrophy in premanifest and early Huntington's disease. *J Huntingtons Dis.* 2013;2(4):517-526. doi:10.3233/JHD-130077
94. Johnson EB, Parker CS, Scahill RI, et al. Altered iron and myelin in premanifest Huntington's Disease more than 20 years before clinical onset: Evidence from the cross-sectional HD Young Adult Study. *EBioMedicine.* 2021;65:103266.
95. Zhang J, Gregory S, Scahill RI, et al. In vivo characterization of white matter pathology in premanifest huntington's disease. *Annals of Neurology.* 2018;84(4):497-504. doi:10.1002/ana.25309
96. Wendler A, Wehling M. The translatability of animal models for clinical development: biomarkers and disease models. *Curr Opin Pharmacol.* 2010;10(5):601-606. doi:10.1016/j.coph.2010.05.009
97. Antonsen BT, Jiang Y, Veraart J, et al. Altered diffusion tensor imaging measurements in aged transgenic Huntington disease rats. *Brain Struct Funct.* 2013;218(3):767-778. doi:10.1007/s00429-012-0427-0